News Detail
Washington, 20 July 2024: Boehringer Ingelheim will sell an unbranded version of AbbVie's reference drug at a 92% discount to gain traction in the Humira (adalimumab) biosimilar market.
Patients will be able to purchase adalimumab-adbm exclusively through GoodRx, an on......
View Details
Source : Pharmaceutical Technolgy
Boehringer Ingelheim
unbranded version of AbbVie's reference drug
Humira (adalimumab) biosimilar
Related News
- Authorities Seize Counterfeit Medicines in UP Raid (20-01-2025)
- Illegal Performance-Enhancing Drugs Seized in Hyderabad Gym Raid (20-01-2025)
- EMA has recommended the approval of the vaccines Bluevac-3 and Syvazul BTV 3 (20-01-2025)
- IPC to host 'World Pharmacopoeia meet' next month (20-01-2025)
- Immuneel Therapeutics launches low cost treatment for blood cancer (20-01-2025)
- Video clip of IIT Madras Director Kamakoti favouring 'Gomutra' goes viral (20-01-2025)
- Puducherry scientist develops high-yielding pepper variety (19-01-2025)
- Pharma firm raided in Baddi by ANTF again (19-01-2025)
- 2.70 lakh Narcotic Pills recovered in Sirsa, driver detained, handed over to DCO (19-01-2025)
- Arrest warrant for Baba Ramdev and Balakrishna (19-01-2025)